Melanoma-associated antigen 1-derived peptide epitope (MAGEA1 peptide epitope)

Melanoma-associated antigen 1 (MAGEA1) is a member of the cancer-testis antigen (CTA) family, which is characterized by restricted expression in the human germline (testis and placenta) and aberrant expression in various histological types of tumors [1]. The MAGEA1-derived peptide epitope, most notably the HLA-A*01-restricted nonamer EADPTGHSY, serves as a highly specific target for cancer immunotherapy because it is presented on the surface of malignant cells but absent from normal somatic tissues [2, 3]. Therapeutic strategies targeting this epitope include peptide-based vaccines and T-cell receptor (TCR) engineered T-cell therapies designed to recognize the peptide-MHC complex [4, 5]. Upon binding, these therapies trigger a potent cytotoxic T-lymphocyte response, leading to the selective destruction of MAGEA1-positive tumor cells [4]. Clinical development has focused on patients with melanoma, lung cancer, and other solid tumors where MAGEA1 is frequently overexpressed [6]. However, challenges remain regarding potential cross-reactivity with other MAGE family proteins and the downregulation of MHC molecules by tumors to evade immune detection [7, 8]. Sources: [1] UniProt P43355; [2] J Exp Med 1992, 176(5):1287-97; [3] Science 1991, 254(5038):1643-7; [4] Cancer Res 2004, 64(1):386-90; [5] Mol Cancer 2011, 10:58; [6] ClinicalTrials.gov; [7] Blood 2013, 122(6):863-71; [8] Front Immunol 2020, 11:582370.

Other names

MAGE-1 peptideMAGE-A1 antigenMelanoma antigen family A 1 peptideEADPTGHSY peptide

Recognition of the peptide-MHC complex by specific T-cell receptors (TCRs) on cytotoxic T-lymphocytes, leading to targeted lysis of MAGEA1-expressing tumor cells.